Tagista, tablets 16 mg 30 pcs

Betahistine acts mainly on histamine H1- and H3-receptors of the inner ear and vestibular nuclei of the CNS.

By direct agonist effect on H1-receptors of the inner ear vessels and indirectly through the effect on NZ-receptors it improves microcirculation and capillary permeability, normalizes endolymph pressure in the labyrinth and cochlea.

At the same time betahistine increases blood flow in the basilar artery.

It has a strong central effect being an inhibitor of NZ-receptors of the vestibular nerve nuclei.

It normalizes the conduction in neurons of the vestibular nuclei at the level of the brain stem.

Clinical manifestation of these properties is reducing the frequency and intensity of dizziness, tinnitus reduction, improvement of hearing in case of its reduction.

Pharmacokinetics

Absorbed quickly, binding with plasma proteins is low. Time to reach maximum concentration in plasma – 3 hours.

It is almost completely eliminated by kidneys in the form of metabolite (2-pyridylacetic acid) within 24 hours. The elimination half-life is 3-4 hours.

Indications

Active ingredient

Composition

1 tablet contains

Active substance:

Betahistine dihydrochloride 8.0 mg; 16.0 mg; 24.0 mg;

Auxiliary substances:

Microcrystalline cellulose, 54.75/109.5/164.25 mg,

Povidone (collidone 25) – 9.0/18.0/27.0 mg

Potato starch – 20.0/40.0/60.0 mg,

Citric acid – 2.0/4.0/6.0 mg,

Silicon dioxide colloid (aerosil), – 3.0/6.0/9.0 mg,

/p>

Talc – 2.8/5.6/8.4 mg,

Magnesium stearate – 0.45/0.9/1.35 mg.

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Symptoms: nausea, vomiting, seizures.

Treatment: gastric lavage, intake of activated charcoal, symptomatic therapy.

Similarities